High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC Study 31/ACTG A5349 phase 3 clinical trial

INTRODUCTION: Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design of an ongoing phas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Contemp Clin Trials
Main Authors: Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Goldberg, Stefan V., Bozeman, Lorna, Burman, William J., Chang, Kwok-Chiu, Chen, Michael, Cotton, Mark, Dooley, Kelly E., Engle, Melissa, Feng, Pei-Jean, Fletcher, Courtney V., Ha, Phan, Heilig, Charles M., Johnson, John L., Lessem, Erica, Metchock, Beverly, Miro, Jose M., Nhung, Nguyen Viet, Pettit, April C., Phillips, Patrick P.J., Podany, Anthony T., Purfield, Anne E., Robergeau, Kathleen, Samaneka, Wadzanai, Scott, Nigel A., Sizemore, Erin, Vernon, Andrew, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307310/
https://ncbi.nlm.nih.gov/pubmed/31981713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2020.105938
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados